Epidermal growth factor receptor inhibition modulates the nuclear localization and cytotoxicity of the Auger electron emitting radiopharmaceutical 111In-DTPA human epidermal growth factor.

Epidermal growth factor receptor inhibition modulates the nuclear localization and cytotoxicity of the Auger electron emitting radiopharmaceutical 111In-DTPA human epidermal growth factor.

UNLABELLED: (111)In-DTPA-human epidermal growth factor ((111)In-DTPA-hEGF [DTPA is diethylenetriaminepentaacetic acid]) is an Auger electron-emitting radiopharmaceutical that targets EGF receptor (EGFR)-positive cancer. The purpose of this study was to determine the effect of EGFR inhibition by gefi...

Full description

Bibliographic Details
Main Authors:	Bailey, K, Costantini, D, Cai, Z, Scollard, D, Chen, Z, Reilly, R, Vallis, K
Format:	Journal article
Language:	English
Published:	2007

Similar Items

Preclinical pharmacokinetic, biodistribution, toxicology, and dosimetry studies of 111In-DTPA-human epidermal growth factor: an auger electron-emitting radiotherapeutic agent for epidermal growth factor receptor-positive breast cancer.
by: Reilly, R, et al.
Published: (2006)

ErbB-2 blockade and prenyltransferase inhibition alter epidermal growth factor and epidermal growth factor receptor trafficking and enhance (111)In-DTPA-hEGF Auger electron radiation therapy.
by: Cornelissen, B, et al.
Published: (2011)

111In-BnDTPA-F3: An Auger electron-emitting radiotherapeutic agent that targets nucleolin
by: Cornelissen, B, et al.
Published: (2012)

111In-BnDTPA-F3: An Auger electron-emitting radiotherapeutic agent that targets nucleolin
by: Cornelissen, B, et al.
Published: (2012)

111In-BnDTPA-F3: an Auger electron-emitting radiotherapeutic agent that targets nucleolin.
by: Cornelissen, B, et al.
Published: (2012)

A phase I trial of In-111-human epidermal growth factor in patients with metastatic EGFR-positive breast cancer
by: Vallis, K, et al.
Published: (2008)

Phase I trial to evaluate the tumor and normal tissue uptake, radiation dosimetry and safety of (111)In-DTPA-human epidermal growth factor in patients with metastatic EGFR-positive breast cancer.
by: Vallis, K, et al.
Published: (2014)

A kit formulated under good manufacturing practices for labeling human epidermal growth factor with 111In for radiotherapeutic applications.
by: Reilly, R, et al.
Published: (2004)

Antitumor effects and normal tissue toxicity of 111In-labeled epidermal growth factor administered to athymic mice bearing epidermal growth factor receptor-positive human breast cancer xenografts.
by: Chen, P, et al.
Published: (2003)

Relationship between induction of phosphorylated H2AX and survival in breast cancer cells exposed to 111In-DTPA-hEGF.
by: Cai, Z, et al.
Published: (2008)

(111)In-labeled trastuzumab (Herceptin) modified with nuclear localization sequences (NLS): an Auger electron-emitting radiotherapeutic agent for HER2/neu-amplified breast cancer.
by: Costantini, D, et al.
Published: (2007)

Methotrexate, paclitaxel, and doxorubicin radiosensitize HER2-amplified human breast cancer cells to the Auger electron-emitting radiotherapeutic agent (111)In-NLS-trastuzumab.
by: Costantini, D, et al.
Published: (2010)

A phase I clinical trial to evaluate the pharmacokinetics, toxicity and dosimetry of 111-indium-labeled human epidermal growth factor in patients with metastatic breast cancer
by: Vallis, K, et al.
Published: (2005)

Trastuzumab-resistant breast cancer cells remain sensitive to the auger electron-emitting radiotherapeutic agent 111In-NLS-trastuzumab and are radiosensitized by methotrexate.
by: Costantini, D, et al.
Published: (2008)

Effect of the EGFR density of breast cancer cells on nuclear importation, in vitro cytotoxicity, and tumor and normal-tissue uptake of [111In]DTPA-hEGF.
by: Hu, M, et al.
Published: (2007)

The anti-tumor effect of the auger electron-emitting radiopharmaceutical, In-111-hEGF against MDA-MB-468 human breast cancer xenografts is tumor-size dependent.
by: Chen, P, et al.
Published: (2001)

Epidermal Growth Factor Receptor in Pancreatic Cancer
by: Ajith K. Siriwardena, et al.
Published: (2011-03-01)

Micro-SPECT/CT with 111In-DTPA-pertuzumab sensitively detects trastuzumab-mediated HER2 downregulation and tumor response in athymic mice bearing MDA-MB-361 human breast cancer xenografts.
by: McLarty, K, et al.
Published: (2009)

Association study between epidermal growth factor receptor and epidermal growth factor polymorphisms and endometriosis in a Japanese population.
by: Inagaki, M, et al.
Published: (2007)

Epidermal growth factor receptor and human epidermal growth factor receptor 2 gene polymorphisms in endometrial cancer in a Japanese population.
by: Kitao, K, et al.
Published: (2007)

111In-labeled immunoconjugates (ICs) bispecific for the epidermal growth factor receptor (EGFR) and cyclin-dependent kinase inhibitor, p27Kip1.
by: Cornelissen, B, et al.
Published: (2009)

The identification and validation of Auger electron-emitting radiopharmaceuticals targeting telomerase for cancer therapy
by: Jackson, M
Published: (2013)

The Role of Epidermal Growth Factor Receptor Mutations and Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in the Treatment of Lung Cancer
by: Shih-Chieh Chang, et al.
Published: (2011-06-01)

The under-appreciated promiscuity of the epidermal growth factor receptor family.
by: Sean P Kennedy, et al.
Published: (2016-08-01)

Red light emitting diode as an adjuvant treatment for epidermal growth factor receptor inhibitors-induced paronychia
by: Chanoknan Jornsamer, et al.
Published: (2022-05-01)

Epidermal Growth Factor Receptor immunohistochemical expression in hepatocellular carcinoma without Epidermal Growth Factor Receptor exons 18–21 mutations
by: Nikolova Dafina, et al.
Published: (2022-09-01)

Epidermal Growth Factor Receptor Expression in the Corneal Epithelium
by: Joanne L. Peterson, et al.
Published: (2021-09-01)

Esophageal Cancer and the Importance of Epidermal Growth Factor (EGFR)
by: Kazem Anvari, et al.
Published: (2014-04-01)

Early signaling dynamics of the epidermal growth factor receptor
by: Reddy, Raven J., et al.
Published: (2017)

Epidermal growth factor receptor blockers for the treatment of ovarian cancer
by: Morrison, J, et al.
Published: (2018)

Associations between the uptake of 111In-DTPA-trastuzumab, HER2 density and response to trastuzumab (Herceptin) in athymic mice bearing subcutaneous human tumour xenografts.
by: McLarty, K, et al.
Published: (2009)

Characterizing the motogenic response of human keratinocytes to epidermal growth factor and transforming growth factor-alpha
by: Rodgers, Stephen D
Published: (2008)

Computational analysis of the number, area and density of gamma-H2AX foci in breast cancer cells exposed to (111)In-DTPA-hEGF or gamma-rays using Image-J software.
by: Cai, Z, et al.
Published: (2009)

Epidermal growth factor/epidermal growth factor receptor signaling axis is a significant regulator of the proteasome expression and activity in colon cancer cells
Published: (2014-09-01)

Targeted Delivery of Epidermal Growth Factor to the Human Placenta to Treat Fetal Growth Restriction
by: Lewis J. Renshall, et al.
Published: (2021-10-01)

Epidermal growth factor receptor mutations in lung adenocarcinoma in Malaysian patients
by: Liam, C.K., et al.
Published: (2013)

A case of epidermal growth factor receptor tyrosine kinase inhibitor effectiveness in epidermal growth factor receptor mutation-positive squamous cell carcinoma
by: Sosuke Matsumura, et al.
Published: (2023-02-01)

Moleculary targeted auger electron radiation therapy for breast cancer: A clinical trial.
by: Vallis, K, et al.
Published: (2004)

Retargeting adenovirus gene therapy via the epidermal growth factor receptor
by: Morrison, J, et al.
Published: (2006)

Epidermal growth factor receptormutations in lung adenocarcinoma in Malaysian patients
by: Liam, Chong Kin, et al.
Published: (2013)